MedTrace Logo

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

NCT05879757 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2026-02-18

No results posted yet for this study

Summary

In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.

Conditions

Interventions

OTHER

No Intervention

As this is an observational study, no intervention will be administered in this study.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-17
Primary Completion
2027-02-16
Completion
2027-02-16

Countries

  • Argentina
  • Czechia
  • France
  • Germany
  • Greece
  • Italy
  • Poland
  • Romania
  • Spain
  • Sweden
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05879757 on ClinicalTrials.gov